Spero Therapeutics enters $100 million share sale agreement with Jefferies
Spero Therapeutics entered an at-the-market share sale agreement with Jefferies LLC as agent on August 28, 2026, allowing it to sell common stock up to $100 million once its $300 million universal shelf registration statement is declared effective. The company also terminated its prior Cantor Fitzgerald at-the-market agreement effective the same day, with no termination penalties and no shares sold under that agreement in fiscal 2024 or 2025. Shareholders could face dilution if the company sells shares under the new agreement, but the filing states no amount has been sold and no sales can occur until the registration is effective.
Key points
- Agreement with Jefferies allows sales of up to $100 million of common stock under the prospectus once the registration statement is effective
- Jefferies compensation is up to 3.0% of gross proceeds from shares sold
- Shelf registration on Form S-3 covers up to $300 million in debt securities, common stock, preferred stock and other securities
- Cantor Fitzgerald sales agreement terminated effective August 28, 2026, with no termination penalties and no shares sold in fiscal 2024 or 2025
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.